#BEGIN_DRUGCARD DB01816

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
79831-76-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H15NO4

# Chemical_IUPAC_Name:
(1S,6S,7R,8R,8aS)-octahydroindolizine-1,6,7,8-tetrol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Enzyme Inhibitors
Immunosuppressive Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
(1s,6s,7r,8r,8ar)-1,6,7,8-Tetrahydroxyindolizidine

# HET_ID:
CTS

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2/t4-,5-,6-,7+,8+/m0/s1

# InChI_Key:
InChIKey=JDVVGAQPNNXQDW-QYYLWSOASA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C02256

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1816

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
189.209

# Molecular_Weight_Mono:
189.100107973

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EQC

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
0.77

# Predicted_Water_Solubility:
1.11e+03 g/l

# Primary_Accession_No:
DB01816

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
11063191

# PubChem_Substance_ID:
46507978

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01055

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]12

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:31 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X56556

# Drug_Target_1_GenBank_ID_Protein:
578126

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
XOG1

# Drug_Target_1_Gene_Sequence:
>1317 bp
ATGCAGTTATCATTTATCTTAACATCATCGGTATTTATATTATTGCTTGAATTTGTTAAA
GCCCTGGTTATTTCTAATCCATTTAAACCAAATGGAAACTTGAAATTCAAGAGAGGAGGC
GGACATAATGTTGCTTGGGATTATGATAATAATGTTATCAGAGGTGTCAATTTGGGTGGT
TGGTTTGTCCTTGAACCATATATGACACCATCACTTTTTGAACCATTCCAAAATGGAAAT
GATCAGTCTGGAGTTCCAGTTGACGAATATCACTGGACACAAACTTTGGGTAAGGAAGCT
GCTCTGAGAATTTTGCAAAAACATTGGAGTACTTGGATCACTGAACAAGACTTTAAACAA
ATTAGTAATTTGGGATTGAACTTTGTTCGTATTCCTATTGGTTATTGGGCTTTCCAATTG
TTGGATAATGATCCATACGTCCAAGGTCAAGTTCAGTATTTGGAAAAGGCTTTGGGCTGG
GCCAGAAAGAATAATATCAGAGTTTGGATTGATTTGCACGGTGCACCAGGCTCTCAAAAT
GGGTTTGACAACTCCGGTTTAAGAGATAGCTACAATTTCCAAAACGGTGATAACACCCAA
GTTACTTTGAATGTATTGAATACTATTTTCAAAAAGTATGGTGGCAACGAATACTCTGAC
GTTGTTATTGGTATTGAATTGCTTAATGAACCATTGGGTCCAGTTTTGAATATGGATAAA
TTGAAACAATTTTTCTTGGATGGTTACAACTCTCTTAGACAAACTGGATCAGTCACCCCA
GTTATCATTCACGATGCTTTCCAAGTCTTTGGCTATTGGAATAACTTTTTGACTGTTGCT
GAAGGTCAATGGAATGTTGTTGTTGACCATCATCATTACCAAGTGTTTTCCGGTGGTGAA
TTATCTCGTAACATTAACGACCACATTTCAGTTGCTTGTAACTGGGGTTGGGATGCTAAA
AAGGAATCCCATTGGAACGTCGCTGGTGAATGGTCTGCTGCTTTGACAGATTGTGCTAAA
TGGTTGAATGGTGTCAACAGAGGAGCACGTTATGAGGGTGCTTACGATAATGCTCCATAC
ATTGGATCCTGTCAACCATTGTTGGATATTTCCCAATGGTCTGATGAACACAAAACCGAC
ACAAGAAGATACATTGAGGCTCAATTGGATGCTTTTGAATACACTGGAGGCTGGGTCTTC
TGGAGTTGGAAGACTGAAAATGCCCCTGAATGGAGTTTCCAAACCTTGACTTACAATGGT
CTTTTCCCACAACCAGTTACTGATAGACAATTCCCAAACCAATGTGGCTTTCACTGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
10610795	Cutfield SM, Davies GJ, Murshudov G, Anderson BF, Moody PC, Sullivan PA, Cutfield JF: The structure of the exo-beta-(1,3)-glucanase from Candida albicans in native and bound forms: relationship between a pocket and groove in family 5 glycosyl hydrolases. J Mol Biol. 1999 Dec 3;294(3):771-83.
1789004	Luna-Arias JP, Andaluz E, Ridruejo JC, Olivero I, Larriba G: The major exoglucanase from Candida albicans: a non-glycosylated secretory monomer related to its counterpart from Saccharomyces cerevisiae. Yeast. 1991 Nov;7(8):833-41.
8436950	Chambers RS, Broughton MJ, Cannon RD, Carne A, Emerson GW, Sullivan PA: An exo-beta-(1,3)-glucanase of Candida albicans: purification of the enzyme and molecular cloning of the gene. J Gen Microbiol. 1993 Feb;139(2):325-34.
9013549	Mackenzie LF, Brooke GS, Cutfield JF, Sullivan PA, Withers SG: Identification of Glu-330 as the catalytic nucleophile of Candida albicans exo-beta-(1,3)-glucanase. J Biol Chem. 1997 Feb 7;272(6):3161-7.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2454

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
50022

# Drug_Target_1_Name:
Glucan 1,3-beta-glucosidase

# Drug_Target_1_Number_of_Residues:
438

# Drug_Target_1_PDB_ID:
1EQC

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00150	Cellulase

# Drug_Target_1_Protein_Sequence:
>Glucan 1,3-beta-glucosidase precursor
MQLSFILTSSVFILLLEFVKASVISNPFKPNGNLKFKRGGGHNVAWDYDNNVIRGVNLGG
WFVLEPYMTPSLFEPFQNGNDQSGVPVDEYHWTQTLGKEAALRILQKHWSTWITEQDFKQ
ISNLGLNFVRIPIGYWAFQLLDNDPYVQGQVQYLEKALGWARKNNIRVWIDLHGAPGSQN
GFDNSGLRDSYNSQNGDNTQVTLNVLNTIFKKYGGNEYSDVVIGIELLNEPLGPVLNMDK
LKQFFLDGYNSLRQTGSVTPVIIHDAFQVFGYWNNFLTVAEGQWNVVVDHHHYQVFSGGE
LSRNINDHISVACNWGWDAKKESHWNVAGEWSAALTDCAKWLNGVNRGARYEGAYDNAPY
IGSCQPMLDISQWSDEHKTDTRRYIEAQLDAFEYTGGWVFWSWKTENAPEWSFQTLTYNG
LFPQPVTDRQFPNQCGFH

# Drug_Target_1_Reaction:
Successive hydrolysis of beta-D-glucose units from the non-reducing ends of 1,3-beta-D-glucans, releasing alpha-glucose ALL_REAC (other) R03115 R06078(G)

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
Beta-glucanases participate in the metabolism of beta- glucan, the main structural component of the cell wall. It could also function biosynthetically as a transglycosylase

# Drug_Target_1_SwissProt_ID:
P29717

# Drug_Target_1_SwissProt_Name:
EXG_CANAL

# Drug_Target_1_Synonyms:
EC 3.2.1.58
Exo-1,3-beta- glucanase
Glucan 1,3-beta-glucosidase precursor

# Drug_Target_1_Theoretical_pI:
5.37

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01816
